Growth Hormone (GH) Replacement Therapy in Adult-Onset GH Deficiency: Effects on Body Composition in Men and Women in a Double-Blind, Randomized, Placebo-Controlled Trial
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Adult GH deficiency (AGHD) is characterized by an altered body composition, an atherogenic lipid profile, decreased exercise capacity, and diminished quality of life. We performed a randomized, double-blind, placebo-controlled, multicenter study in 166 subjects with AGHD to assess the effects of GH on these outcomes. GH was initiated at 0.0125 mg/kg.d, increased to 0.025 mg/kg.d as tolerated, or decreased to 0.00625 mg/kg.d for 12 months. Primary measures of efficacy included body composition, strength and endurance, and quality of life. Additional parameters included serum IGF-I concentrations, serum lipids, and bone mineral density. After 12 months, 79% of subjects remained on GH 0.0125 mg/kg.d, whereas 21% received 0.00625 mg/kg.d. GH-treated men and women demonstrated significant decreases in total body and trunk fat and increases in lean body mass over baseline. In GH-treated men, mean IGF-I SD scores exceeded age-adjusted normal ranges, whereas similar doses produced a smaller response in women. GH treatment was associated with significant improvements in total cholesterol and low-density lipoprotein (P < 0.05 for all). No significant treatment effects were observed in strength and endurance, quality of life, or bone mineral density. GH treatment was generally well tolerated. Subjects with AGHD should receive individualized GH therapy to maintain IGF-I between the mean value and +2 SD and improve body composition and cardiovascular risk factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lean body mass cardiac stroke volume and left ventricular mass are increased (170).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [170]
In the citing paper
“Serum lipoprotein profiles improve with reduced total and LDL cholesterol and increased high-density lipoprotein (HDL) cholesterol, triglycerides, and ApoB 100 levels (170).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [170]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 54 · Cited by 185
Metadata
- Authors
- Hoffman, A. R., Kuntze, J. E., Baptista, J., Baum, H. B. A., Baumann, G. P., Biller, B. M. K., Clark, R. V., Cook, D., Inzucchi, S. E., Kleinberg, D., Klibanski, A., Phillips, L. S., Ridgway, E. C., Robbins, R. J., Schlechte, J., Sharma, M., Thorner, M. O., & Vance, M. L.
- Affiliations
- VA Palo Alto Health Care System (US)
- Genentech (US)
- Harvard University (US)
- Northwestern University (US)
- Duke Medical Center (US)
- Oregon Health & Science University (US)
- Yale University (US)
- Veterans Health Administration (US)
- Emory University (US)
- University of Colorado Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Iowa (US)
- George Washington University (US)
- University of Virginia (US)
- Corresponding author
- Hoffman, Andrew R.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-05
- Volume
- 89
- Issue
- 5
- Pages
- 2048-2056
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2154533640
- Semantic Scholar
- 8c6866c25df775357460489c4b94453362a1cd14
- Cited by
- 185
- References
- 54
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 7 · 2021: 3 · 2020: 8 · 2019: 4 · 2018: 14 · 2017: 8 · 2016: 7 · 2015: 7 · 2014: 11 · 2013: 11 · 2012: 6
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Genentech
- Stanford Bio-X
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- growth hormone replacement therapy, adult-onset growth hormone deficiency, body composition, lean body mass, trunk fat, insulin-like growth factor I, serum lipids, low-density lipoprotein, total cholesterol, bone mineral density, strength and endurance, quality of life, sex differences, dose titration
- MeSH terms
- Adult, Aged, Anthropometry, Body Composition, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Insulin-Like Growth Factor I, Lipids, Male, Metabolism, Inborn Errors, Middle Aged, Physical Endurance, Placebos, Quality of Life, Recombinant Proteins, Muscle, Skeletal, Human Growth Hormone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Growth Hormone (GH) Replacement Therapy in Adult-Onset GH Deficiency: Effects on Body Composition in Men and Women in a Double-Blind, Randomized, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.1210/jc.2003-030346
- The paper
- Hoffman, A. R., Kuntze, J. E., Baptista, J., Baum, H. B. A., Baumann, G. P., Biller, B. M. K., Clark, R. V., Cook, D., Inzucchi, S. E., Kleinberg, D., Klibanski, A., Phillips, L. S., Ridgway, E. C., Robbins, R. J., Schlechte, J., Sharma, M., Thorner, M. O., & Vance, M. L. (2004). Growth Hormone (GH) Replacement Therapy in Adult-Onset GH Deficiency: Effects on Body Composition in Men and Women in a Double-Blind, Randomized, Placebo-Controlled Trial. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2003-030346
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.